Study Design. A systematic review of nonspecific low back pain trials published between 1980 and 2012. Objective. To explore what proportion of trials have been powered to detect different bands of effect size; whether there is evidence that sample size in low back pain trials has been increasing; what proportion of trial reports include a sample size calculation; and whether likelihood of reporting sample size calculations has increased. Summary of Background Data. Clinical trials should have a sample size sufficient to detect a minimally important difference for a given power and type I error rate. An underpowered trial is one within which probability of type II error is too high. Metaanalyses do not mitigate underpowered trials. Methods. Reviewers independently abstracted data on sample size at point of analysis, whether a sample size calculation was reported, and year of publication. Descriptive analyses were used to explore ability to detect effect sizes, and regression analyses to explore the relationship between sample size, or reporting sample size calculations, and time. Results. We included 383 trials. One-third were powered to detect a standardized mean difference of less than 0.5, and 5% were powered to detect less than 0.3. The average sample size was 153 people, which increased only slightly ($4 people/yr) from 1980 to 2000, and declined slightly ($4.5 people/yr) from 2005 to 2011 (P < 0.00005). Sample size calculations were reported in 41% of trials. The odds of reporting a sample size calculation (compared to not reporting one) increased until 2005 and then declined ðOR year ¼ 1:06; OR year 2 ¼ 0:99; P < 0:00005Þ. Conclusion. Sample sizes in back pain trials and the reporting of sample size calculations may need to be increased. It may be justifiable to power a trial to detect only large effects in the case of novel interventions.
S
tatistical tests in clinical trials generally test null hypotheses that differences between populations are zero. 1 Customarily, type I error rate (or alpha) is set at 0.05, i.e., rejection of the null hypothesis if there is <5% probability it is true, given the observed result. Also customarily, the power of the study, i.e., the probability of detecting a difference if one truly exists in the population, is usually set at 80% or 90%.
The magnitude of the difference between groups that a study is powered to detect should be based on the population-difference that is perceived as worthwhile, i.e., the (population-level) minimally important difference (MID). 2, 3 Nonspecific low back pain (nsLBP) trials utilize many different outcome measures, in different units, but outcomes can be standardized by dividing the between-group difference by the standard deviation to produce a standardized effect size (ES; also referred to as a standardized mean difference), which allows magnitudes of difference to be compared across trials regardless of the units of the outcome measurement scale. [4] [5] [6] Conventionally, ESs of 0.2 are considered small, 0.5 medium, and 0.8 large. 7 Whether or not a difference magnitude can be considered worthwhile (i.e., a MID) may depend on both the type of intervention (e.g., how invasive it is or any disadvantages of having it) and the cost of providing the treatment in question. 8, 9 Large, From the high-quality trials suggest that effective interventions often have ESs of around 0.3 notwithstanding the type of intervention. 4, 10, 11 In this paper, we refer to such magnitudes of difference as ''typical'' for nsLBP interventions. If a trial is underpowered then there is a greater risk of type II error, i.e., failing to detect a difference when one truly exists in the population. 1 Thus, assuming good internal validity, it is difficult to interpret outcomes in trials reporting null results in cases where sample sizes are small; it may be either that there is no population difference, or it may be type II error. It has been suggested that in these cases, metaanalyses of underpowered studies provide remedy. 12 However, nsLBP populations may often be too heterogeneous to permit sensible pooling in fixed effects models, and randomeffects models make assumptions about population distributions that may be unrealistic. [13] [14] [15] [16] Additionally, pooling of different outcomes purporting to measure the same domains, with outcomes described in terms of ES, may be unsafe. 17 Further, therapist-delivered interventions testing the same basic intervention may be so dissimilar, and poorly specified, that it is not possible to describe the intervention evaluated by the meta-analysis in a manner that would allow replication. For these reasons, properly powered high-quality trials, which can be viewed as definitive, may be preferable. Meta-analyses of all trials report larger effect sizes than the single most precise trial and this finding is more marked when subjective outcome measures (which are common in nsLBP) 6 are used. 18 There have been several calls to increase sample sizes in trials over the past decades, and the importance of undertaking sample size calculations has been emphasized. 1, [19] [20] [21] The impact that calls and checklists have had on practice relating to power and reporting sample size calculations in back pain trials is unclear.
Our aims were to explore: (A) what proportion of nsLBP trials have been powered to detect bands of effect size ranging between small 
MATERIALS AND METHODS
Two reviewers (RF, SP) independently identified randomized controlled trials (RCTs), published from 1980 inclusive, of interventions for nonspecific low back pain (nsLBP) from COST-B13's European Guidelines for the Management of Low Back Pain (EGLBP) and from the systematic reviews reported in the EGLBP. 22 The EGLBP search was extended in two phases. In 2007, two reviewers (RF, SP) searched from November 2002, when the COST-B13 search finished, to the end of December 2006, using the Cochrane library, PubMed, EMBASE, HTA, and Lilacs databases. In 2012, three reviewers (PB, DR, TB) searched from January 2007 to January 2012, using PubMed, EMBASE, and the Cochrane library, within which the majority of nsLBP trials are indexed. Supplemental Digital Content file 1 (PDF, http://links.lww.com/BRS/B228) shows a typical search string. Table 1 shows inclusion and exclusion criteria.
We combined material from the EGLBP and extended searches, removing duplicates, and short-listing by title and abstract. Full-texts were obtained if the titles and abstract alone contained insufficient information for assessment against criteria in Table 1 .
All five reviewers abstracted data from the trials on numbers analyzed for the primary outcome for the prespecified main comparison, details of whether or not a sample size calculation was reported, and the year of publication. An outcome was identified as ''primary'' if (A) the outcome was nominated as such; if no outcome was nominated, or if multiple outcomes were nominated, we used (B) the outcome measure on which the sample size calculation was based; if this was not reported, we identified (C) the first outcome measure referred to in the abstract; and if this was not identified, we used (D) the first outcome mentioned in Studies that were not RCTs or presented insufficient information for us to determine whether randomisation was used to allocate participants 3
Reports that self-identified as pilot/feasibility studies 4
Cross-over designs (because of limited utility in the LBP field) 5
RCTs with mixed samples (e.g., neck or thoracic pain in addition to LBP), samples of participants with radiating leg pain, or referred pain extending past the knee, or samples including LBP specific pathology (e.g., cancer, ankylosing spondylitis, or disc herniation) or pregnancy 6 Trials using solely objective or psychological outcome measures 7
Noninferiority designs 8
Follow-up studies with no new outcome measures, and multiple publications. In the case of multiple publications, we included the first published article and excluded subsequent publications nsLBP indicates nonspecific low back pain; RCT, randomized controlled trial.
the paper. This approach has been taken in several other methodological reviews. 6, [23] [24] [25] We identified the primary end-point, or used the first follow-up time point in cases when this was not clear. Disagreements were resolved through discussion and, if necessary, with arbitration involving an independent reviewer (RF, SE, or MU). Reporting of sample size calculation was judged present if, as a minimum, it was reported how many participants were estimated as required to detect a given between-group difference, or if the latter was not reported, if the detectable between-group difference could be readily calculated from what was reported. The calculations needed to be a priori. We judged calculations to have been a priori, if these were phrased in terms of the number of participants that it was calculated would be needed to achieve a given power. Post hoc calculations that estimated how much power a trial had, based on the number of included participants, were not counted.
For all data abstraction we used expert validation of 20% of papers, as has been done in other methodological reviews. 26 It was decided a priori that in the case of agreement being less than 80%, full independent abstraction would be undertaken. Validation disagreements were settled by arbitration involving an independent reviewer.
For each trial, the average sample size by arm was calculated and compared to the threshold of participants needed to detect an ES of small ( 
, under the assumption of comparisons to groups of approximately equal size. Trials were categorized according to their ability to detect within these bands. 5 The proportion of trials reporting sample size calculations was calculated by year. To explore our objective of whether sample size is increasing with time, we used linear regression with a log-transformation of sample size to control for the heteroschedasticity (i.e., the changing variance) of sample size on year. To explore the likelihood of reporting a sample size calculation by time, we fitted a logit model, regressing reporting of sample size (binary) on year. Nonlinear relationships between predictor and outcome variables were explored through fitting polynomial terms in predictor variables and log rank tests were used to test these terms for statistical significance (a ¼ 0.05). Model fit was examined using residual plots, and in the case of the logit model, a combination of Pseudo R 2 , AIC, and residual plots. Locally weighted least squares (Lowess) smoothers were added if they aided interpretations of trends over time. All analyses were performed in Stata, version 12 (Statacorp, TX).
RESULTS
From our combined searches, we sifted a total of 7066 hits, removing 4398 of these based on titles and abstracts and 1931 duplicates, and assessed 737 papers at full-text level. We rejected 354 papers that did not fit our inclusion criteria. 11 We included 383 trials (Figure 1 
Ability of Trials to Detect Effect Sizes
Across all trials, the average total sample size was 152.8 (IQR ¼ 126; range 12-2594). Figure 2 shows histograms of average group size and logged average group size, with reference guidelines for ES detection ability. Table 2 shows the frequency of trials by ES detection category. The majority (67.1%) of trials were only powered to detect ES of greater than 0.5 (medium).
Sample Size Over Time
A quadratic term in year was required to adequately model sample size over time (i.e., the relationship follows a quadratic curve rather than a line (P <0.0005)). 
Reporting of Sample Size Calculations in General
Across the whole time period of interest, the proportion of trials in which a sample size calculation was reported is 41% (95% CI 36.3-46.4).
Likelihood of Reporting Sample Size Calculations by Time
From the logit model, the odds ratio for reporting a sample size calculation by year is 1.093 (1.06-1.13), P <0.00005, Pseudo R 2 ¼ 6.7% (i.e., very strong evidence of an increase in odds of reporting sample size calculation of 9% per year). However, model fit is improved by adding quadratic term in year (i.e., the increase in odds of reporting sample size calculation curves over time), P ¼ 0. linear predictor), the constant, when year is unadjusted and year 2 is centered on its average, is À115.806. 
DISCUSSION

Main Findings
The results show that around one-third of trials have been powered to detect a medium ES mean difference of less than 0.5 and around 5% were powered to detect magnitudes of less than 0.3. There is very strong evidence for an increase of sample size over time from 1980. The increase is trivial in magnitude and slips into a decline from 2005. We found that sample size calculations are reported in 41% of trials published between 1980 and 2012. The likelihood of reporting sample size calculations increases by several percent each year, and begins to decrease after 2005.
Implications
Large, high-quality trials of interventions for back pain that convincingly demonstrate effectiveness may suggest typical ESs for nsLBP interventions are around 0.3, between 1980 and 2012. 4, 10, 11 We found that 5% of published trials have had sufficient power to detect such magnitudes. There may be a culture of conducting underpowered trials in the field of nsLBP research that needs to be addressed, i.e., with the distribution of sample size shown in Figure 2 needing to be right-shifted.
As explained in the Introduction, meta-analytic techniques do not mitigate underpowered trials, as even using random effects models, assumptions must be made about the between-study heterogeneity that may often be invalid; especially in cases where heterogeneity may be due to methodological reasons rather than clinical heterogeneity. 16 That said, there may be a place for smaller trials. As many larger high-quality trials of interventions for low back pain demonstrate only small-to-moderate differences, a counterargument can be made that continuing to do these will do little to progress the field. Smaller well-conducted trials of novel interventions, which are only powered to detect larger effect sizes, could indicate promising avenues for intervention development. In such cases, a clear rationale for the approach and care to describe the novel intervention would facilitate subsequent replication in confirmatory trials.
In 1992, Cohen 1 pointed out that while there is no disagreement between methodologists on the utility of sample size calculations, progress over the last 25 years had been slow. In the quarter-century that followed his observation we have shown that progress continues to be slow, with a decline in the reporting of sample size calculations from 2005 onward. One reason for the decline may be that in recent years, some alternative approaches to sample size calculations have been proposed, which may have had the effect of deemphasising the importance of sample size calculations and power. 12 A common thread of these arguments involves dependence on systematic reviews, which as outlined, may not be ideal.
By not reporting a priori sample size calculations, the majority of trial reports are not consistent with the 2010 CONSORT statement (item 7a). One implication may be that these have not been performed, meaning that, if the situation continues, trial protocols may also not conform to the 2013 SPIRIT checklist (item 14).
As change to improve sample sizes and the reporting of sample size calculations would need to be affected at the level of individual trialists, the implication is that trialists, funders, peer-reviewers, journal editors, and authors would each have a role to play.
Comparisons to Existing Research
Castellini et al, in 2016, reviewed RCTs of mechanical low back pain published after 1968. Among 222 included studies, they found that 36% reported a sample size calculation, but only 16% reported what they deemed complete calculations. They found that both reporting and completeness of reporting improved between 1968 and 2013, and show a relative decline in the proportion reporting sample size calculations since 2005. This is consistent with our data. Their point estimate that 36% report sample size calculations is slightly less than ours. We suggest the following possible reasons: (A) Castellini's work dates back to publications in the late 1960s, which predates several calls for improvements in sample size (although only eight trials (3.6%) predate 1980); (B) our sample is based on 58% more trials; (C) Castellini's search used the terms ''rehabilitation,'' so the population may have been slightly less general than ours; and (D) we required a priori reporting of the number of participants required to detect a given between-group difference, as minimum criteria to judge reporting the calculation. While it is clear how Castellini judged completeness of reporting of sample size calculations, it is not clear whether minimal criteria were used to judge reporting of a basic sample size calculation.
Moher et al 19 reviewed 383 trials, published between 1975 and 1990, exploring their power to detect 25% and 50% relative differences if null results were reported. They found that 25% reported null results, and of these only 16% and 36% had the power to detect these magnitudes of difference. They observed that these percentages did not increase over time. While our results are not directly comparable, we found that sample size in general has increased over time, albeit by trivial magnitude, until 2005. Moher also found that in trials reporting null results 32% reported sample size calculations and that this increased from 0% in 1975 to 43%, in 1990. Since we did not separately explore reporting in trials reporting null results, our results are not directly comparable. However, we also observed an increase over time, at least until 2005. Given both Moher's and our results, we note the implication that in 1990, the likelihood of reporting a sample size calculation seems greater if the trial reported a null result.
Strengths and Limitations
This work provides a useful account of trends of sample sizes in back pain trials and reporting of sample size calculations. It comes from a comprehensive review of trials that were published between 1980 and 2012, during which time there were several calls to ensure such trials had appropriate sample sizes. 1, [19] [20] [21] One limitation of our work is that we did not consider the extent of the reporting of sample size calculations or likelihood of reporting by positive or negative results. This work was part of a larger systematic review addressing several other methodological research questions and these aspects were not prioritized; however, we acknowledge Castillini's and Moher's useful contributions here. 19 Caution should be noted in using the quadratic models for future prediction, as trajectories of falls will be predicted to continue along the quadratic curves, which peaked in 2000 and 2005, respectively. Should any authors like to update the model we will be happy to share our data. We could have described our findings descriptively, but model fitting was useful insofar as it demonstrates the trend and the weight of evidence for the observations.
CONCLUSION
We found that 5% of trials published between 1980 and 2012 were powered to detect effect sizes of less than 0.3, and around one-third were powered to detect effect sizes of less than 0.5. Therefore, the majority of trials may be underpowered to detect small-to-medium between-group differences. There is evidence of an increase in sample size calculations between 1980 and 2012, but this is trivial in magnitude, and declines after 2005. If the authors do not perform, or continue not to report, a priori sample size calculations in the future, this will be inconsistent with the SPIRIT checklist, or the CONSORT statement, respectively.
Trialists should plan to make the size of nsLBP trials large enough to detect small-to-medium effect sizes and report sample size calculations. It may be justifiable to power a trial only to detect large effect sizes in the case of testing novel interventions that might reasonably be expected to have larger effect sizes.
Key Points
Around one-third of trials are powered to detect an effect size of less than 0.5 and 5% are powered to detect effect sizes of less than 0.3. Sample sizes in back pain trials have increased by a small magnitude since 1980 and have declined since 2005. Sample size calculations are reported in 41% of trials, and since 2005 the proportion reporting sample size calculations has fallen. Except for cases in which novel interventions are being tested, and a small sample size is clearly justified by design, back pain trial sample sizes may need to be increased, with the required size being established a priori and reported in publications.
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